Navigation Links
Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
Date:12/5/2010

a (SLL): An Update on Ongoing Phase 1 Studies" is being presented by Jan Burger MD, PhD. This abstract describes clinical data from a pooled analysis of 54 CLL/SLL patients from a Phase Ia (N=16) and a Phase Ib/II (N=38) study.  Patients from the Phase Ia trial have relapsed/refractory CLL/SLL and have been treated for a median of approximately 8 months, while patients on the Phase Ib/II trial include two cohorts—one with relapsed or refractory disease and one with treatment-naive disease—who were just recently enrolled.

Response data from the pooled analysis is presented below.  Outcomes are described based on strict application of standard response criteria, with an additional outcome category termed "nodal response with lymphocytosis." This category describes patients with substantial lymph node (LN) shrinkage who have not yet achieved a 50% decrease of malignant B cells in the blood (lymphocytosis). The inclusion of this category is necessary because of the unique characteristics of response to this agent, especially early in treatment.  From the Ia trial, with approximately 8 months median follow-up, 1 patient achieved a complete response (CR) and 8/13 evaluable patients achieved a partial response (PR) for an objective response rate of 69%. Two additional patients achieved a nodal response with lymphocytosis (15%) and 2 patients had stable disease (SD).  Of note, 3 of the patients now classified as partial responses were initially nodal response with lymphocytosis earlier in treatment. In the Ib/II trial, with less than 2 months median follow-up, 8/32 evaluable patients achieved a PR (25%) by standard response criteria with an additional 17/32 (53%) achieving a nodal response with lymphocytosis.  Six other patients have SD. As noted previously, study of the patients from the Ia trial suggest that blood lymphocytosis decreases over time on treatment and patients who initially are described as nodal responses with lym
'/>"/>

SOURCE Pharmacyclics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
2. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
3. Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
4. Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
5. Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results
6. Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7
7. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
8. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
11. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... August 20, 2014 Phase I ... the US  KalVista Pharmaceuticals ("KalVista"), an ophthalmology ... today announces that it has begun a Phase I, ... inhibitor, KVD001, for the treatment of DME. The study,s ... Beetham Eye Institute, Joslin Diabetes Center; Harvard Medical School ...
(Date:8/19/2014)... 19, 2014 Talyst, a market leader in ... the 2014 NPPA Summer Conference in Las ... its 340B software products and services.   ... supplying over 400 customers with a variety of software ... including its latest solution, AutoSplit® Contract Pharmacy and 340B ...
(Date:8/19/2014)... 2014 /PRNewswire-iReach/ -- ChemImage founder and CTO, Patrick ... describing an innovative diagnostic procedure for the detection of ... on Disease (SPEC) conference in Krakow, Poland ... "Development of in vitro Diagnostics for Detection of Colorectal ... the conference poster session on Tuesday, August 19, 2014 ...
Breaking Medicine Technology:KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4Talyst Exhibits at the NPPA Summer Conference 2ChemImage Scientists Present Latest Developments for in vitro Detection of Colorectal Cancer Using Raman Molecular Imaging (RMI) at International Conference Focused on Biomedical Applications of Raman Spectroscopy 2
... March 15 Sequenom, Inc. (Nasdaq: SQNM ) today reported its financial results for the fourth quarter and year ended December 31, 2009 . , ... , , ... ...   http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO ) , ...
... March 15 International Merchant Advisors, ... today that the company has completed the purchase of ... Inc. in an all stock transaction.  Organic Science, Inc. will ... this business segment, and is focused on the ...
Cached Medicine Technology:Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 2Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 3Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 4Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 5Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 6Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 7Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 8Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 9Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 10Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 11Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 12Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 13Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 14Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 15Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results 16International Merchant Advisors Completes All Stock Based Purchase of Medical Marijuana Company Organic Science, Inc. 2International Merchant Advisors Completes All Stock Based Purchase of Medical Marijuana Company Organic Science, Inc. 3
(Date:8/20/2014)... August 20, 2014 It’s no secret ... According to the National Institute on Drug Abuse, nearly ... drugs. What’s even more alarming is the fact that ... last decade. , Those locked in a struggle with ... way out. But now, the newly-redesigned AbuseTreatmentCenters.net has released ...
(Date:8/20/2014)... New York, NY (PRWEB) August 20, 2014 ... the world’s largest nutrition school, is proud to ... of Integral Studies (CIIS), a cutting-edge university ... Integrative Nutrition’s Health Coach Training Program are now ... Master of Arts in Integrative Health Studies. , ...
(Date:8/20/2014)... A Missouri federal judge has remanded a lawsuit filed ... GranuFlo and NaturaLyte to the City of St. Louis Circuit ... The judge rejected an assertion by the defendants that the ... et al. v. Fresenius Medical Care North America Inc., et ... the manufacturer of the dialysis products GranuFlo and NaturaLyte. In ...
(Date:8/20/2014)... 2014 Botanica Day Spa ... Utilizing the new and popular stem cell line ... lines and wrinkles and naturally repairs the skin. ... the new service by offering clients a complimentary ... cell facial. , Pevonia® continues to be a ...
(Date:8/20/2014)... 2014 (HealthDay News) -- Taking the widely ... dying from heart-related causes, a new study suggests. ... the findings require urgent confirmation, said the Danish researchers ... risk is small and that guidelines for the use ... information is available. One heart expert wasn,t surprised ...
Breaking Medicine News(10 mins):Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 2Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 3Health News:GranuFlo/NaturaLyte Case Remanded to State Court By Missouri Federal Judge, Baron and Budd Reports 2Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 2Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 3Health News:Antibiotic Might Raise Heart Risks for Some 2
... Organisation (WHO) Monday hailed the progress of governments of Western ... region needed greater effort to effectively control the disease. ... of detecting at least 70 percent of TB cases and ... Maaren, regional adviser for the health body's TB programme. ...
... miniature robot that can be inserted through an incision ... body. ,Researchers from Ritsumeikan University and the ... that is controlled remotely once placed inside the body. ... centimeters (0.79 inches) in length and one in diameter. ...
... that some patients who complete bariatric surgery can develop ... deficiency, called Wernicke encephalopathy. , The researchers ... about their conclusions by extensive survey of data relating ... surgery. , The syndrome - Wernicke encephalopathy ...
... inhaled anesthetics increase the number of amyloid plaques in ... of neurodegenerative diseases like Alzheimer's. ,Roderic Eckenhoff, ... Pennsylvania's Department of Anesthesia and Critical Care, and his ... edition of Neurobiology of Aging. ,Every year ...
... hardly 29 per cent of the asthmatic children surveyed had ... as a dangerous trend for not vaccinating their kids against ... officials have warned. ,Actually it has been warned ... fall victims to pneumonia or acute respiratory disease. Inactivated flu ...
... possibly hazardous chemicals called polybrominated diphenyl ethers (PBDEs). The ... and Technology and the Environmental Protection Agency of the ... clear how dangerous these PBDEs are, though some types ... is strikingly similar to that of PCBs, which are ...
Cached Medicine News:Health News:WHO Calls for Greater Efforts to Fight TB 2Health News:Inhaled Anesthetics Accelerate the Onset of Neurodegenerative Diseases Like Alzheimer's 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: